Actelion Ltd. (SW:ATLN) Initiates Phase IIb/III Program With Clazosentan
10/19/2005 5:08:49 PM
ALLSCHWIL, Switzerland, Dec. 22, 2004 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced today it has initiated the comprehensive global Phase IIb/III development program for clazosentan, an intravenous endothelin receptor antagonist. This follows the completion of discussions with regulatory authorities in both the US and the European Union on all aspects of the clinical program, including clinical efficacy endpoints.
comments powered by